Novartis faces fresh patent cliff after trial setbacks
CNBC · RSS · · AI-summarised by FinFlash
Novartis is working to build its next generation of blockbuster medicines after a series of clinical trial setbacks, with disappointing data underscoring the difficulty of replacing revenue lost as older drugs lose patent protection. The Swiss pharma giant is moving past one patent cliff while another looms.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.